GlassScriptPhysician profile
Vijay Oza
NPI 1144424516
$2,490.04
in general payments reported to CMS, 2019-2025
25 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $225 · 2021: $325 · 2022: $288 · 2023: $271 · 2024: $557 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.01 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.10 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $278.42 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $211.17 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $190.71 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $124.94 | 2020-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
| Abbott Laboratories | $97.44 | 2021-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $65.89 | 2022-2025 | Zoryve |
| Amgen INC. | $65.80 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $51.08 | 2024-2025 | |
| Pfizer INC. | $50.91 | 2020-2025 | |
| Dexcom, INC. | $49.22 | 2021-2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $46.47 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $41.94 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Novartis Pharmaceuticals Corporation | $33.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $28.45 | 2019 | |
| Medtronic, INC. | $26.94 | 2024 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.83 | 2024 | |
| Althera Pharmaceuticals LLC | $25.52 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.68 | 2022 | |
| Lundbeck LLC | $19.49 | 2024 | Rexulti |
| Optinose US, INC. | $19.21 | 2025 | |
| Biogen, INC. | $18.43 | 2023 | Spinraza |
| Exact Sciences Corporation | $17.33 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Oza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.